4th Immunogenicity (description)


Address:Holiday Inn Kensington Forum, 97 Cromwell Road, London, , United Kingdom SW7 4DN
Event dates:6/12/2017 - 6/13/2017 (This event has already taken place)
Event web site:
findCE GPA: This event is not yet rated. Click here to view a sample report card
Click here to rate 4th Immunogenicity


Topics to be Covered:

  • Regeneron, EpiVax Inc., Boehringer Ingelheim, ProImmune Ltd, UCB, Roche, Selecta Biosciences, Novartis, NIBSC, MHRA, EpiVax Inc, AbbVie, INSERM, Merck and many more
  • Science, Health and Medicine
  • Pharmaceuticals
Organizer phone:02078276012
Offering type:Conference
Specialty:Data not provided
Event frequency:Never
First Meeting:
Total events:
Est. attendance:
Target audience:Any
Other target audiences:
Host Sponsor:SMi Group
Est. # of exhibitors:
Currency:British Pounds
CE Credits:
Organizer URL


SMi is thrilled to present the return of its 4th annual Immunogenicity conference and exhibition, taking place in London on the 12th – 13th June 2017.

The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.

This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

. Guidance on UK, EU and USA regulations surrounding immunogenicity and best practice risk assessment
. Targeted focus on immunogenicity; identifying, addressing and removing challenges to industry
. Highlight best practice risk assessment and mitigation through high level case studies
. Explore novel and innovative approaches to reducing immunogenicity
. Spotlight on new technology; Humanising proteins and new biotherapeutic solutions
. Personalising treatments with next generation biologic drugs


Time: 8:30 am to 4:30 pm

Registration Fee Details:

Book by 31 March: GBP 1199
Book By 28 April: GBP 1299
Book By 31 May: GBP 1399
Standard: GBP 1499

Other items that tuition includes:

Travel and hotel arrangements:

Contact Person:Kyra Williams
Organizer State/Province: (Outside US)
Organizer CountryData not provided
Organizer Phone02078276012
Structural makeupOrganization
Host Sponsor; Other SponsorsSMi Group
Event sold out?No
Multiple locations or dates?No
Statistics available for most recent event held in:NA
Average number in event attendance of:
Number in attendance of:
Target BoundariesInternational
Is Registration contact information the same as Organizer Contact above?Yes
Web Page
Can one register for your CE on your web site?NA
Can registration be made by snail (regular) mail?Yes
Online housing reservations: 
Do you have additional written or AV materials for sale?No
If so, are they available for non-attendees as well as those attending?NA
Is full tuition necessary to ensure registration?No
Will there be shuttle service available?NA
Additional notes:Booking:

Sign In/Sign Out
About Us
Contact Us